GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy (NCT06636123)

🧪 Interventions in This Study

• Investigational Agent Administration (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Virginia Commonwealth University — Richmond, Virginia

📞 Contact the Study Coordinator

Phone: (804) 628-6430

Email: masseyepd@vcu.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Castration-resistant Prostate Cancer

• pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer — St Louis, Missouri
• Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer — La Jolla, California
• Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer — Duarte, California

Explore by condition: All Castration-resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.